Esperion Therapeutics ESPR Unrecognized Tax Benefits
Unrecognized Tax Benefits at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:UnrecognizedTaxBenefits.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's unrecognized tax benefits.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's unrecognized tax benefits?
- Esperion Therapeutics (ESPR) reported unrecognized tax benefits of $3.4M in Q4 2025.
- How has Esperion Therapeutics's unrecognized tax benefits changed year-over-year?
- Esperion Therapeutics's unrecognized tax benefits increased by 62.1% year-over-year, from $2.1M to $3.4M.
- What is the long-term trend for Esperion Therapeutics's unrecognized tax benefits?
- Over 5 years (2020 to 2025), Esperion Therapeutics's unrecognized tax benefits has grown at a 5.5% compound annual growth rate (CAGR), from $2.61M to $3.4M.
- What does unrecognized tax benefits mean?
- This represents the amount of tax benefits from uncertain tax positions that have not been recognized in the financial statements because they do not meet the 'more-likely-than-not' threshold. It reflects the company's exposure to potential tax audits and disputes with tax authorities. This is a key indicator of tax-related legal and financial risk.